UBS Maintains a 'Neutral' on InterMune (ITMN); Shionogi Moves Ahead on Royalty Demands

UBS maintains a 'Neutral' on InterMune Inc. (NASDAQ: ITMN) price target of $13.50.

Analyst, Matthew Harrison, noted the 8-K filed last Friday, regarding a compliant filed against the company from Shionogi & Co. which alleges InterMune breached an agreement between InterMune and Shionogi governing the exchange and use of certain documents and information relating to the parties' respective clinical trials of pirfenidone...The compliant also alleges that ITMN has failed to pay royalties for sales of pirfenidone (Esbriet) in the EU.

For an analyst ratings summary and ratings history on InterMune Inc. click here. For more ratings news on InterMune Inc. click here.

Shares of InterMune Inc. closed at $11.79 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform